, a n e  m  e  n  t  s   T  h  e  a  u  t  h  o  r  s  w  o  u  l  d  l  i  k  e  t  o  t  h  a  n  k  t  h  e  I  D  I  B  A  P  S  G  e  n  o  m  i  c  s  C  o  r  e  F  a  c  i  l  i  t  y  a  n  d  t  h  e   H  e  m  a  t  o  p  a  t  h  o  l  o  g  y  C  o  l  l  e  c  t  i  o  n  f  r  o  m  H  o  s  p  i  t  a  l  C  l  i  n  i  c  /  I  D  I  B  A  P  S  ;  t  h  e  M  o  l  e  c  u  l  a  r  C  y  t  o  g  e  n  e  t  i  c   P  l  a  t  f  o  r  m  o  f  I  M  I  M  ,  H  o  s  p  i  t  a  l  d  e  l  M  a  r  (  B  a  r  c  e  l  o  n  a  )  f  o  r  p  r  o  v  i  d  i  n  g  o  n  e  I  G  K  B  A  C  c  l  o  n  e  .   M  i  r  i  a  m  P  r  i  e  t  o  ,  S  i  l  v  i  a  M  a  r  t  í  n  ,  C  á  n  d  i  d  a  G  ó  m  e  z  ,  a  n  d  A  m  p  a  r  o  A  r  i  a  s  f  o  r  t  h  e  i  r  e  x  c  e  l  l  e  n  t   t  e  c  h  n  i  c  a  l  a  s  s  i  s  t  a  n  c  e  a  n  d  M  o  n  t  s  e  r  r  a  t  P  u  i  g  g  r  ò  s  a  n  d  R  o  m  i  n  a  R  o  y  o  f  r  o  m  B  a  r  c  e  l  o  n  a   S  u  p  e  r  C  o  m  p  u  t  i  n  g  C  e  n  t  e  r  .  T  h  i  s  w  o  r  k  w  a  s  d  e  v  e  l  o  p  e  d  a  t  t  h  e  C  e  n  t  r  o  E  s  t  h  e  r  K  o  p  l  o  w  i  t  z   (  C  E  K  )  ,  B  a  r  c  e  l  o  n  a  ,  S  p  a  i  n  . C  y  c  l  i  n  D  1  +  m  a  n  t  l  e  c  e  l  l  l  y  m  p  h  o  m  a  (  M  C  L  )  i  s  m  o  l  e  c  u  l  a  r  l  y  c  h  a  r  a  c  t  e  r  i  z  e  d  b  y  t  h  e   t  (  1  1  ;  1  4  )  (1  3  ;3  2  )  o  r  r  e  a  r  r  a  n  g  e  m  e  n  t  s  o  f   C  C  N  D  1   g  e  n  e  w  i  t  h  t  h  e  i  m  m  u  n  o  g  l  o  b  u  l  i  n  (  I  G  )   l  i  g  h  t  c  h  a  i  n  s  .   1  ,  2   M  o  s  t  M  C  L  c  a  n  b  e  d  i  a  g  n  o  s  e  d  b  a  s  e  d  o  n  t  h  e  c  h  a  r  a  c  t  e  r  i  s  t  i  c  p  a  t  h  o  l  o  g  i  c   f  e  a  t  u  r  e  s  a  n  d  c  y  c  l  i  n  D  1  e  x  p  r  e  s  s  i  o  n  w  i  t  h  o  u  t  t  h  e  n  e  e  d  f  o  r  d  e  m  o  n  s  t  r  a  t  i  n  g  t  h  e  g  e  n  e  t  i  c   t  r  a  n  s  l  o  c  a  t  i  o  n  .  H  o  w  e  v  e  r  ,  i  n  c  a  s  e  s  w  i  t  h  a  t  y  p  i  c  a  l  m  o  r  p  h  o  l  o  g  i  c  o  r  p  h  e  n  o  t  y  p  i  c  f  e  a  t  u  r  e  s   o  t  h  e  r  B  -c  e  l  l  n  e  o  p  l  a  s  m  s  t  h  a  t  s  o  m  e  t  i  m  e  s  a  l  s  o  h  a  v  e  c  y  c  l  i  n  D  1  p  o  s  i  t  i  v  i  t  y  m  a  y  b  e  i  n  t 
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SUPPLEMENTARY METHODS

Case selection and immunohistochemistry
We studied 4 mantle cell lymphoma and one mature B-cell neoplasm with marked plasmacytic differentiation, all with strong cyclin D1 expression but the t(11;14)
translocation or CCND1 rearrangements were not found using conventional cytogenetics or FISH with fusion or break-apart probes. All the original haematoxylin and eosin stained sections or newly stained sections were reviewed. Immunohistochemical stains were performed for each case on 2 μm thick sections using a peroxidase-labeled detection system, standard antigen retrieval protocols, and an automated immunostainer (AutostainerLink 48, Dako, Glostrup, Denmark or BenchmarkXT, Roche Diagnostics, Basel, Switzerland) as previously described 1 or phenotype information was retrieved from the original reports (Online Supplementary Table S1 ). 
FISH analysis
Copy number and next-generation sequencing (NGS)
Copy number alterations were investigated using Oncoscan FFPE or SNP6.0 Array (ThermoFisher Scientific, Waltham, MA) and analyzed as described previously using Nexus Biodiscovery v9 (Biodiscovery, Hawthorne, CA, USA). 4, 5 Paired-end whole-genome sequencing was performed on tumor and germline DNA from case 1 using standard Illumina protocols and sequenced in an Illumina HiSeq 2000 instrument. 4 Smufin, 6 Lumpy, 7 and custom algorithms were used to detect genome-wide structural variants (SV) and potential cryptic CCND1 rearrangements. Single nucleotide variant and indel calling was performed by Smufin and Sidrón, 8 and copy number alterations analysis was performed by Battenberg (https://github.com/cancerit/cgpBattenberg) (manuscript with additional details in preparation).
The mutational status of 115 genes previously described in aggressive B-cell lymphoma was examined by targeted NGS strategy (Online Supplementary Table S3 ).
Libraries were prepared with 150 ng of genomic DNA using SureSelect XT Target Enrichment System Capture strategy (Agilent Technologies Inc.) and sequenced in a MiSeq instrument (Illumina, 2x150bp). The bioinformatics analysis was performed using an updated version of our previously validated pipeline. 9 The mean coverage was 564x (range 363x-1020x) with >90% of target region covered >200x. Synonymous, intronic variants, and polymorphisms reported in dbSNP149 database with a European population frequency higher than 1% (1000 Genomes Project, ExAC, or gnomAD database) or present in our custom chronic lymphocytic leukemia (CLL) database 10 were removed. ACTB  CD79A  GNAI2  MAP2K1  PIK3CD  STAT3  ARID1A  CD79B  HIST1H1B  MAPK1  PIM1  STAT6  ARID1B  CD83  HIST1H1C  MCL1  POU2F2  TBL1XR1  ARID5B  CDKN2A  HIST1H1D  MEF2B  PRDM1  TCF3  ATM  CDKN2B  HIST1H1E  MFHAS1  PRKCB  TET2  B2M  CIITA  HLA-A  MIR147*92  PTEN  TMEM30A  BCL10  CREBBP  HLA-B  MYC  PTPRD  TMSB4X  BCL2  CXCR4  HLA-C  MYD88  REL  TNFAIP3  BCL6  DDX3X  HVCN1  NFKBIA  RHOA  TNFRSF14  BCOR  DIS3  ID3  NFKBIE  RRAGC  TNIP1  BRAF  DTX1  IRF2BP2  NFKBIZ  S1PR1  TOX  BTG1  EBF1  IRF4  NOTCH1  S1PR2  TP53  BTG2  EP300  IRF8  NOTCH2  SETD1B  XBP1  BTK  ETS1  ITPKB  NRAS  SETD2  XPO1  CARD11  ETV6  KLHL14  OSBPL10  SF3B1  ZEB2  CCND3  EZH2  KLHL6  P2RY8  SGK1  CD274  FAS  KMT2D  PARP2  SMARCA4  CD36  FBXW7  KRAS  PAX5  SOCS1  CD58  FOXO1  MALT1  PCBP1  SPEN  CD70  GNA13  MAML1 PIK3CA SPIB 
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